MG

MeiraGTx Holdings plc

MGTXHealthcareNASDAQ

Biotechnology

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$81.4M
+144.6% YoY
Net Income
-$114.2M
+22.7% YoY
EBITDA
-$89.4M
+26.6% YoY
Free Cash Flow
$56.4M

Scan Results

Daily timeframe
DateIndicatorDetails
Sep 3 MACD Negative CrossoverHistogram -0.0723, negative momentum
Sep 2 MACD Negative CrossoverHistogram -0.0564, negative momentum
About MeiraGTx Holdings plc

Part of the healthcare sector, MeiraGTx Holdings plc (MGTX) is listed under Biotechnology. At a $1.33B market cap, MeiraGTx Holdings plc ranks as a small-cap company within healthcare. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.

Where MGTX stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, MGTX finished 37.44% above its 150-day moving average ($10.23) and 45.55% above its 200-day moving average ($9.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is MGTX overbought or oversold?

At the September 3, 2026 close, MGTX's RSI(14) was 63.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$1.33B
P/E (TTM)15.97
Fwd P/E-9.99
EPS$0.87
Beta1.27
52W Change+81.6%
ROE72.2%
Analysis

MeiraGTx Holdings plc holds $143.2M in cash against $112.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $56.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 72.2%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 38.6% further supports the picture of efficient asset utilization. Revenue has grown from $15.9M (2022) to $81.4M (2025), reflecting a 411% increase over the period.

Investors considering MeiraGTx Holdings plc should weigh the typical risks associated with MGTX's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing MGTX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms